Table 4 Recent Prospective Trials of Recurrent High-grade Glioma
Treatment | Author, Year | Regimen | Median Dose(Gy) | Sample Size(N) | MST (Months) |
|---|---|---|---|---|---|
Systemic Therapy | Reardon, 2017 [8] | Nivolumab vs BVZ | N/A | Nivo = 184 BVZ = 185 | 9.8 vs 10.0 |
Wick, 2017 [9] | Lomustine +BVZ vs Lomustine | N/A | L + BVZ = 228 L = 149 | 9.1 vs 8.6 | |
Friedman, 2009 [10] | BVZ vs BVZ + CPT11 | N/A | BVZ = 85 BVZ + CPT11 = 82 | 9.2 vs 8.7 | |
TTF | Stupp, 2012 [12] | TTField vs Chemotherapy | N/A | TTF = 120 Chemotherapy = 117 | 6.6 vs 6 |
HSRT | Clarke, 2017 [13] | HSRT+BVZ | 30 | 15 | 12.5 |
Miwa, 2014 [14] | HSRT+TMZ | 30 | 21 | 12.0 | |
Wuthrick, 2014 [15] | HSRT+Sunitinib | 35 | 11 | 12.7(GBM) |